This review aims to explore the current state of knowledge and therapeutic advancements of RAF and MEK inhibitors’ evaluation in preclinical and clinical cases of mostly BRAF-mutant lung cancer hoping to provide new insights for a more precise and rational therapeutic design and pharmacological intervention. This evidence concerns the gene BRAF and lung cancer.